查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球自体免疫疾病诊断市场（按产品、检测类型、疾病类型、最终用户和地区划分）- 预测至 2031 年
市场调查报告书
商品编码
1788519

全球自体免疫疾病诊断市场（按产品、检测类型、疾病类型、最终用户和地区划分）- 预测至 2031 年

Autoimmunity Diagnostics Market by Product (Consumables, Instruments), Test Type (Routine, Autoantibody, Inflammatory, Urinalysis Tests), Disease (RA, SLE, MS, IBD), End User (Clinical Laboratories, Hospitals & Clinics) - Global Forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 299 Pages | 订单完成后即时交付

价格

自体免疫疾病诊断市场预计将从 2025 年的 55.7 亿美元成长到 2031 年的 89.8 亿美元，预测期内的复合年增长率为 8.3%。

调查范围
调查年份 2024-2031
基准年 2024
预测期 2025-2031
对价单位 金额（十亿美元）
部分 按产品、按测试类型、按疾病类型、按最终用户、按地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

这一增长得益于自体免疫疾病盛行率的上升、早期诊断意识的增强以及多重免疫检测和基于生物标记的检测等技术的进步。此外，自动化平台的日益普及以及政府的支援措施也促进了检测量的增加和诊断准确性的提高。

自体免疫诊断市场-IMG1

根据疾病类型，全球自体免疫疾病诊断市场可细分为系统性自体免疫疾病和器官特异性自体免疫疾病。系统性自体免疫疾病在2024年占据了最大的市场占有率。该地区的巨大份额归因于类风湿性关节炎、全身性红斑性狼疮和多发性硬化症等疾病的高发性。这些疾病通常影响多个器官和系统，需要频繁且全面的诊断评估。诊断的复杂性、对先进免疫学检测的依赖以及对持续疾病监测的需求，正在推动该领域对诊断解决方案的需求。

根据最终用户，自体免疫疾病诊断市场细分为临床实验室、医院和诊所以及其他最终用户。其中，临床实验室凭藉其专业知识、先进的诊断技术和高通量能力占据了最大的市场占有率。这些实验室配备了酵素连结免疫吸附试验 (ELISA)、化学冷光和萤光等自动化平台，能够以高精度和高效率执行复杂的检测。作为集中式检测中心，它们能够以较低的单次检测成本处理大量样本。

自体免疫疾病诊断市场细分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。预计亚太市场在预测期内将实现最高复合年增长率。该地区的高成长率主要得益于自体免疫疾病盛行率的上升、医疗支出的增加、先进诊断技术的普及以及新兴经济体对早期疾病检测意识的不断增强。此外，医疗基础设施的改善和政府的支持措施也促进了亚太地区市场的扩张。

本报告研究了全球自体免疫疾病诊断市场，按产品、测试类型、疾病类型、最终用户和区域趋势进行细分，并提供了参与市场的公司概况。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章重要考察

第五章市场概述

  • 介绍
  • 市场动态
  • 定价分析
  • 专利分析
  • 价值链分析
  • 供应链分析
  • 贸易分析
  • 生态系分析
  • 波特五力分析
  • 主要相关人员和采购标准
  • 技术分析
  • 2025-2026年主要会议和活动
  • 影响客户业务的趋势/中断
  • 投资金筹措场景
  • 案例研究分析
  • 人工智慧/产生人工智慧对自体免疫疾病诊断市场的影响
  • 川普关税对自体免疫疾病诊断市场的影响

第六章自体免疫疾病诊断市场（按产品）

  • 介绍
  • 耗材
  • 装置

第七章自体免疫疾病诊断市场（依检验类型）

  • 介绍
  • 自体抗体和免疫学检测
  • 定期进行实验室检查
  • 发炎检测
  • 尿液检查
  • 其他的

第八章自体免疫疾病诊断市场（依疾病类型）

  • 介绍
  • 系统性自体免疫疾病
  • 器官特异性自体免疫疾病

第九章自体免疫疾病诊断市场（按最终用户）

  • 介绍
  • 临床实验室
  • 医院和诊所
  • 其他的

第 10 章自体免疫疾病诊断市场（按地区）

  • 介绍
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第十一章竞争格局

  • 介绍
  • 主要参与企业的策略/优势
  • 2022-2024年收益分析
  • 2024年市场占有率分析
  • 公司估值矩阵：2024 年关键参与企业
  • 公司估值矩阵：Start-Ups/中小企业，2024 年
  • 估值和财务指标
  • 品牌/产品比较
  • 竞争场景

第十二章：公司简介

  • 主要参与企业
    • F. HOFFMANN-LA ROCHE LTD.
    • ABBOTT LABORATORIES
    • REVVITY, INC.
    • THERMO FISHER SCIENTIFIC INC.
    • SIEMENS HEALTHINEERS AG
    • BIO-RAD LABORATORIES, INC.
    • GRIFOLS SA
    • WERFEN SA
    • EXAGEN INC.
    • TRINITY BIOTECH PLC
    • TECAN GROUP LTD.
    • DANAHER CORPORATION
    • BIOSYNEX SA
    • QUIDELORTHO CORPORATION
    • BIOMERIEUX SA
    • DIASORIN SPA
  • 其他公司
    • BECTON, DICKINSON AND COMPANY
    • SD BIOSENSOR, INC.
    • CAMBRIDGE LIFE SCIENCES LTD
    • A. MENARINI DIAGNOSTICS SRL
    • SEBIA
    • KRONUS
    • ERBA GROUP
    • AESKU.GROUP GMBH
    • MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
    • EPITOPE DIAGNOSTICS INC.

第十三章 附录

Product Code: MD 5936

The autoimmune disease diagnosis market is projected to reach USD 8.98 billion by 2031 from USD 5.57 billion in 2025, at a CAGR of 8.3% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2031
Base Year2024
Forecast Period2025-2031
Units ConsideredValue (USD billion)
SegmentsProduct, Test Type, Disease Type, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

This growth is driven by the rising prevalence of autoimmune disorders, increasing awareness of early diagnosis, and technological advancements such as multiplex immunoassays and biomarker-based tests. Additionally, the growing adoption of automated platforms and supportive government initiatives contribute to increased testing volumes and improved diagnostic accuracy.

Autoimmunity Diagnostics Market - IMG1

By disease type, the systemic autoimmune diseases segment accounted for the largest market share in 2024.

Based on disease type, the global autoimmune disease diagnosis market is segmented into systemic autoimmune diseases and organ-specific autoimmune diseases. The systemic autoimmune diseases segment accounted for the largest market share in 2024. The large share of this region is attributed to the widespread prevalence of conditions such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. These diseases typically affect multiple organs and systems, necessitating frequent and comprehensive diagnostic evaluations. The complexity of diagnosis, reliance on advanced immunological tests, and the need for continuous disease monitoring drive higher demand for diagnostic solutions in this segment.

By end user, the clinical laboratories segment accounted for the largest market share during the forecast period.

Based on end users, the autoimmune disease diagnosis market is segmented into clinical laboratories, hospitals & clinics, and other end users. Among these, the clinical laboratories segment accounted for the largest market share owing to specialized expertise, advanced diagnostic technologies, and high-throughput capabilities. Equipped with automated platforms such as ELISA, chemiluminescence, and immunofluorescence, these laboratories can perform complex tests with high accuracy and efficiency. Their role as centralized testing hubs allows them to process large sample volumes at reduced per-test costs.

Asia Pacific: The fastest-growing region in the autoimmune disease diagnosis market during the forecast period.

The autoimmune disease diagnosis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the region is primarily driven by the rising prevalence of autoimmune diseases, increasing healthcare expenditure, the growing adoption of advanced diagnostic technologies, and heightened awareness about early disease detection across emerging economies. Additionally, improvements in healthcare infrastructure and supportive government initiatives further contribute to market expansion in the Asia Pacific region.

The break-up of the profile of primary participants in the autoimmune disease diagnosis market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, the Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa- 4%

The key players in the market are Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Grifols S.A. (Spain), Werfen S.A. (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Exagen Inc. (US), Trinity Biotech plc (Ireland), Tecan Group Ltd. (Switzerland), Danaher Corporation (US), BIOSYNEX SA (France), QuidelOrtho Corporation (US), Revvity, Inc. (US), bioMerieux SA (France), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), SD Biosensor, INC. (Korea), Cambridge Life Sciences Ltd (UK), A. Menarini Diagnostics s.r.l (Italy), Sebia (France), KRONUS (US), Erba Group (Czech Republic), AESKU.GROUP GmbH (Germany), Medsource Ozone Biomedicals Pvt. Ltd. (India), and Epitope Diagnostics Inc. (US).

Research Coverage:

This research report categorizes the autoimmune disease diagnosis market by product (consumables and instruments), by test type (routine laboratory tests, inflammatory tests, autoantibodies and immunologic tests, urinalysis tests, and other tests), by disease type (systemic autoimmune diseases and organ-specific autoimmune diseases), by end user (clinical laboratories, hospitals & clinics, and other end users), and by region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report's scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the autoimmune disease diagnosis market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the autoimmune disease diagnosis market. This report covers the competitive analysis of upcoming startups in the autoimmune disease diagnosis market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall autoimmune disease diagnosis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (High incidence of autoimmune diseases, rising awareness related to early disease diagnosis, growing number of r&d activities for innovative diagnostic solutions, advancements in diagnostic technologies), restraints (high capital requirements), opportunities (utilization of biosensors for autoimmune disease diagnosis, growth potential of emerging economies, growing number of reagent rental agreements), and challenges (complexities associated with diagnosis of autoimmune diseases, shortage of skilled professionals) influencing the growth of the autoimmune disease diagnosis market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the autoimmune disease diagnosis market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the autoimmune disease diagnosis market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoimmune disease diagnosis market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Revvity, Inc. (US), Thermo Fisher Scientific Inc. (US), and Siemens Healthineers AG (Germany).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 KEY STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key secondary sources
      • 2.1.1.2 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Key primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
      • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.2.1.3 Growth forecast
      • 2.2.1.4 CAGR projections
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.4 MARKET SHARE ASSESSMENT
  • 2.5 RESEARCH ASSUMPTIONS
    • 2.5.1 PARAMETRIC ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 AUTOIMMUNITY DIAGNOSTICS MARKET OVERVIEW
  • 4.2 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2031
  • 4.3 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2031
  • 4.4 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2031
  • 4.5 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2031
  • 4.6 AUTOIMMUNITY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 High incidence of autoimmune diseases
      • 5.2.1.2 Rising awareness related to early disease diagnosis
      • 5.2.1.3 Increasing number of R&D activities for innovative diagnostic solutions
      • 5.2.1.4 Advancements in diagnostic technologies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High capital requirements
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Utilization of biosensors for autoimmune disease diagnosis
      • 5.2.3.2 Growth potential of emerging economies
      • 5.2.3.3 Growing number of reagent rental agreements
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complexities associated with diagnosis of autoimmune diseases
      • 5.2.4.2 Shortage of skilled professionals
  • 5.3 PRICING ANALYSIS
    • 5.3.1 INDICATIVE SELLING PRICE TREND, BY PRODUCT, 2023-2025
    • 5.3.2 INDICATIVE SELLING PRICE TREND OF ASSAYS, BY KEY PLAYER, 2023-2025
    • 5.3.3 INDICATIVE SELLING PRICE TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, BY REGION, 2023-2025
  • 5.4 PATENT ANALYSIS
    • 5.4.1 LIST OF MAJOR PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT DATA (HS CODE 3822)
    • 5.7.2 EXPORT DATA (HS CODE 3822)
  • 5.8 ECOSYSTEM ANALYSIS
    • 5.8.1 ROLE IN ECOSYSTEM
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.10.2 BUYING CRITERIA
    • 5.10.3 REGULATORY LANDSCAPE
      • 5.10.3.1 North America
        • 5.10.3.1.1 US
        • 5.10.3.1.2 Canada
      • 5.10.3.2 Europe
        • 5.10.3.2.1 Germany
        • 5.10.3.2.2 UK
        • 5.10.3.2.3 France
        • 5.10.3.2.4 Italy
      • 5.10.3.3 Asia Pacific
        • 5.10.3.3.1 China
        • 5.10.3.3.2 Japan
        • 5.10.3.3.3 India
        • 5.10.3.3.4 Australia
      • 5.10.3.4 Latin America
      • 5.10.3.5 Middle East
        • 5.10.3.5.1 Africa
    • 5.10.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 TECHNOLOGY ANALYSIS
    • 5.11.1 KEY TECHNOLOGIES
      • 5.11.1.1 Immunoassays
    • 5.11.2 COMPLEMENTARY TECHNOLOGIES
      • 5.11.2.1 Flow cytometry
  • 5.12 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.14 INVESTMENT & FUNDING SCENARIO
  • 5.15 CASE STUDY ANALYSIS
    • 5.15.1 CASE STUDY 1: LABORATORY-BASED DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
    • 5.15.2 CASE STUDY 2: DIAGNOSTIC IMPORTANCE OF AUTOANTIBODY TESTING IN IDENTIFICATION OF LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA)
  • 5.16 IMPACT OF AI/GENERATIVE AI ON AUTOIMMUNITY DIAGNOSTICS MARKET
    • 5.16.1 INTRODUCTION
    • 5.16.2 MARKET POTENTIAL OF AI
    • 5.16.3 AI USE CASES
    • 5.16.4 IMPLEMENTATION OF AI, BY KEY COMPANY AND CASE
    • 5.16.5 FUTURE OF AI IN AUTOIMMUNITY DIAGNOSTICS MARKET
  • 5.17 TRUMP TARIFF IMPACT ON AUTOIMMUNITY DIAGNOSTICS MARKET
    • 5.17.1 INTRODUCTION
    • 5.17.2 KEY TARIFF RATES
    • 5.17.3 PRICE IMPACT ANALYSIS
    • 5.17.4 KEY IMPACT ON COUNTRY/REGION
      • 5.17.4.1 North America
      • 5.17.4.2 Europe
      • 5.17.4.3 Asia Pacific
    • 5.17.5 IMPACT ON END-USE INDUSTRIES
      • 5.17.5.1 Clinical laboratories
      • 5.17.5.2 Hospitals & clinics

6 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 CONSUMABLES
    • 6.2.1 RECURRING PURCHASE FOR HIGH VOLUME OF DIAGNOSTIC TESTING TO PROPEL MARKET
  • 6.3 INSTRUMENTS
    • 6.3.1 GROWING NEED FOR AUTOMATION AND HIGH-THROUGHPUT TESTING TO DRIVE MARKET

7 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE

  • 7.1 INTRODUCTION
  • 7.2 AUTOANTIBODIES AND IMMUNOLOGIC TESTS
    • 7.2.1 ACCURATE DETECTION & MONITORING ABILITIES FOR BROAD APPLICATIONS TO PROPEL MARKET
  • 7.3 ROUTINE LABORATORY TESTS
    • 7.3.1 RECURRENT TESTING DUE TO COST EFFICIENCY TO BOOST DEMAND
  • 7.4 INFLAMMATORY TESTS
    • 7.4.1 ABILITY OF INFLAMMATORY MARKERS TO DETECT ABNORMALITIES TO DRIVE MARKET
  • 7.5 URINALYSIS TESTS
    • 7.5.1 TECHNOLOGICAL ADVANCEMENTS IN URINE ANALYZERS TO FUEL UPTAKE
  • 7.6 OTHER TESTS

8 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE

  • 8.1 INTRODUCTION
  • 8.2 SYSTEMIC AUTOIMMUNE DISEASES
    • 8.2.1 RHEUMATOID ARTHRITIS
      • 8.2.1.1 Uptake of rheumatoid factor immunological test to boost demand
    • 8.2.2 SYSTEMIC LUPUS ERYTHEMATOSUS
      • 8.2.2.1 Utilization of autoimmune testing kits for constant monitoring to propel market
    • 8.2.3 PSORIASIS
      • 8.2.3.1 Frequent association with systemic inflammation and comorbidities to boost demand
    • 8.2.4 MULTIPLE SCLEROSIS
      • 8.2.4.1 Public-private investments for MS awareness to fuel market
    • 8.2.5 OTHER SYSTEMIC AUTOIMMUNE DISEASES
  • 8.3 ORGAN-SPECIFIC AUTOIMMUNE DISEASES
    • 8.3.1 TYPE-1 DIABETES
      • 8.3.1.1 Rising global incidence among children & adults to fuel market
    • 8.3.2 CELIAC DISEASE
      • 8.3.2.1 Growing awareness regarding gluten sensitivity and improved testing availability to drive market
    • 8.3.3 INFLAMMATORY BOWEL DISEASE
      • 8.3.3.1 Growing awareness of chronic gastrointestinal autoimmune disorders to fuel market
    • 8.3.4 OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASES

9 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 CLINICAL LABORATORIES
    • 9.2.1 ABILITY TO CONDUCT HIGH VOLUME OF SPECIALIZED TESTS TO PROPEL MARKET
  • 9.3 HOSPITALS & CLINICS
    • 9.3.1 GROWING AWARENESS OF EARLY DISEASE DIAGNOSIS TO FUEL UPTAKE
  • 9.4 OTHER END USERS

10 AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
    • 10.2.2 US
      • 10.2.2.1 High healthcare expenditure and expansive research initiatives for product commercialization to boost demand
    • 10.2.3 CANADA
      • 10.2.3.1 Rising prevalence of chronic autoimmune conditions to drive market
  • 10.3 EUROPE
    • 10.3.1 EUROPE: MACROECONOMIC OUTLOOK
    • 10.3.2 UK
      • 10.3.2.1 Growing R&D efforts for early disease diagnosis to fuel uptake
    • 10.3.3 GERMANY
      • 10.3.3.1 Increasing incidence of multiple sclerosis to drive market
    • 10.3.4 FRANCE
      • 10.3.4.1 Expansion of lab modernization to support market growth
    • 10.3.5 ITALY
      • 10.3.5.1 Growing disease burden and aging demographics to fuel market
    • 10.3.6 SPAIN
      • 10.3.6.1 Prevalence of celiac disease to drive market
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
    • 10.4.2 CHINA
      • 10.4.2.1 Government initiatives for early autoimmune disease screening to fuel market
    • 10.4.3 JAPAN
      • 10.4.3.1 Rapidly aging population and advanced healthcare infrastructure to boost demand
    • 10.4.4 INDIA
      • 10.4.4.1 Government-led healthcare initiatives and rapid expansion of diagnostic infrastructure to propel market
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Increasing incidences of autoimmune diseases to support market growth
    • 10.4.6 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 INCREASING INCIDENCE OF TYPE-1 DIABETES TO FUEL MARKET
    • 10.5.2 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 FAVORABLE GOVERNMENT INITIATIVES FOR EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET GROWTH
    • 10.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET
  • 11.3 REVENUE ANALYSIS, 2022-2024
  • 11.4 MARKET SHARE ANALYSIS, 2024
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Region footprint
      • 11.5.5.3 Product footprint
      • 11.5.5.4 Test type footprint
      • 11.5.5.5 Disease type footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
      • 11.6.5.1 Detailed list of key startups/SMEs
      • 11.6.5.2 Competitive benchmarking of startups/SMEs
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS
    • 11.7.1 FINANCIAL METRICS
    • 11.7.2 COMPANY VALUATION
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES & APPROVALS
    • 11.9.2 DEALS
    • 11.9.3 EXPANSIONS
    • 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 F. HOFFMANN-LA ROCHE LTD.
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 MnM view
        • 12.1.1.3.1 Key strengths
        • 12.1.1.3.2 Strategic choices
        • 12.1.1.3.3 Weaknesses & competitive threats
    • 12.1.2 ABBOTT LABORATORIES
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 MnM view
        • 12.1.2.3.1 Key strengths
        • 12.1.2.3.2 Strategic choices
        • 12.1.2.3.3 Weaknesses & competitive threats
    • 12.1.3 REVVITY, INC.
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Product launches
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Key strengths
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses & competitive threats
    • 12.1.4 THERMO FISHER SCIENTIFIC INC.
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Product launches
        • 12.1.4.3.2 Deals
        • 12.1.4.3.3 Other developments
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Key strengths
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses & competitive threats
    • 12.1.5 SIEMENS HEALTHINEERS AG
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Product approvals
        • 12.1.5.3.2 Deals
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Key strengths
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses & competitive threats
    • 12.1.6 BIO-RAD LABORATORIES, INC.
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
    • 12.1.7 GRIFOLS S.A.
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Deals
    • 12.1.8 WERFEN S.A.
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Product approvals
    • 12.1.9 EXAGEN INC.
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Product launches
        • 12.1.9.3.2 Deals
    • 12.1.10 TRINITY BIOTECH PLC
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products offered
    • 12.1.11 TECAN GROUP LTD.
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products offered
    • 12.1.12 DANAHER CORPORATION
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products offered
      • 12.1.12.3 Recent developments
        • 12.1.12.3.1 Deals
    • 12.1.13 BIOSYNEX SA
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products offered
      • 12.1.13.3 Recent developments
        • 12.1.13.3.1 Deals
    • 12.1.14 QUIDELORTHO CORPORATION
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products offered
      • 12.1.14.3 Recent developments
        • 12.1.14.3.1 Expansions
    • 12.1.15 BIOMERIEUX SA
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products offered
    • 12.1.16 DIASORIN S.P.A.
      • 12.1.16.1 Business overview
      • 12.1.16.2 Products offered
      • 12.1.16.3 Recent developments
        • 12.1.16.3.1 Deals
  • 12.2 OTHER PLAYERS
    • 12.2.1 BECTON, DICKINSON AND COMPANY
    • 12.2.2 SD BIOSENSOR, INC.
    • 12.2.3 CAMBRIDGE LIFE SCIENCES LTD
    • 12.2.4 A. MENARINI DIAGNOSTICS S.R.L
    • 12.2.5 SEBIA
    • 12.2.6 KRONUS
    • 12.2.7 ERBA GROUP
    • 12.2.8 AESKU.GROUP GMBH
    • 12.2.9 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
    • 12.2.10 EPITOPE DIAGNOSTICS INC.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 AUTOIMMUNITY DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 2 AUTOIMMUNITY DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 NIH-FUNDED INVESTMENTS & GRANTS, BY DISEASE TYPE
  • TABLE 4 A FEW RECENT EXAMPLES OF INNOVATIONS IN AUTOIMMUNE DIAGNOSTIC TECHNOLOGIES ARE LISTED BELOW:
  • TABLE 5 INDICATIVE SELLING PRICING TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, 2023-2025
  • TABLE 6 INDICATIVE SELLING PRICE TREND OF ASSAYS, BY KEY PLAYER, 2023-2025
  • TABLE 7 INDICATIVE SELLING PRICE TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, BY REGION, 2023-2025
  • TABLE 8 AUTOIMMUNITY DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS, 2023-2024
  • TABLE 9 IMPORT DATA (HS CODE 3822), BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 10 EXPORT DATA (HS CODE 3822), BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 11 AUTOIMMUNITY DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • TABLE 12 AUTOIMMUNITY DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS (%)
  • TABLE 14 KEY BUYING CRITERIA FOR AUTOIMMUNITY DIAGNOSTICS PRODUCTS
  • TABLE 15 CLASSIFICATION OF IVD DEVICES IN EUROPE
  • TABLE 16 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
  • TABLE 17 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 AUTOIMMUNITY DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
  • TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 24 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 25 KEY COMPANIES OFFERING CONSUMABLES
  • TABLE 26 AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 27 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 28 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 30 KEY COMPANIES OFFERING INSTRUMENTS
  • TABLE 31 AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 32 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 33 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 34 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 35 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 36 AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 37 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 38 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 40 AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 41 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 42 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 44 AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 45 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 46 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 48 AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 49 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 50 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 52 AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 53 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 54 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 56 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 57 SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 58 SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 59 NORTH AMERICA: SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 60 EUROPE: SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 62 KEY COMPANIES CURRENTLY OFFERING RHEUMATOID ARTHRITIS PRODUCTS
  • TABLE 63 AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 64 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 65 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 67 KEY COMPANIES CURRENTLY OFFERING SYSTEMIC LUPUS ERYTHEMATOSUS PRODUCTS
  • TABLE 68 AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 69 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 70 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 72 AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 73 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 74 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 76 KEY COMPANIES CURRENTLY OFFERING MULTIPLE SCLEROSIS PRODUCTS
  • TABLE 77 AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 78 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 79 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 81 KEY COMPANIES CURRENTLY OFFERING OTHER SYSTEMIC AUTOIMMUNE DISEASE PRODUCTS
  • TABLE 82 OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 83 NORTH AMERICA: OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 84 EUROPE: OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 85 ASIA PACIFIC: OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 86 ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 87 ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 88 NORTH AMERICA: ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 89 EUROPE: ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 91 NUMBER OF PEOPLE LIVING WITH TYPE 1 DIABETES, 2024
  • TABLE 92 KEY COMPANIES CURRENTLY OFFERING TYPE 1 DIABETES PRODUCTS
  • TABLE 93 AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE 1 DIABETES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 94 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE

1 DIABETES, BY COUNTRY, 2023-2031 (USD MILLION)

  • TABLE 95 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE 1 DIABETES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE 1 DIABETES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 97 KEY COMPANIES OFFERING CELIAC DISEASE PRODUCTS
  • TABLE 98 AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 99 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 100 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 102 KEY COMPANIES OFFERING INFLAMMATORY BOWEL DISEASE PRODUCTS
  • TABLE 103 AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 104 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 105 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 107 KEY COMPANIES CURRENTLY OFFERING OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASE PRODUCTS
  • TABLE 108 OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 109 NORTH AMERICA: OTHER ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 110 EUROPE: OTHER ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: OTHER ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 112 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 113 AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 114 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 115 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 117 NUMBER OF HOSPITALS, BY COUNTRY, 2023
  • TABLE 118 AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 119 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 120 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 122 AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 123 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 124 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 126 AUTOIMMUNITY DIAGNOSTICS MARET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 127 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 128 NORTH AMERICA: NUMBER OF RHEUMATOID ARTHRITIS (RA) CASES, BY COUNTRY, 2023-2031
  • TABLE 129 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 130 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 131 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 132 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 133 NORTH AMERICA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 134 NORTH AMERICA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 135 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 136 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 137 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 138 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 139 US: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 140 US: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 141 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 142 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 143 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 144 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 145 CANADA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 146 CANADA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 147 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 148 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 149 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 150 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 151 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 152 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 153 EUROPE: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 154 EUROPE: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 155 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 156 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 157 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 158 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 159 UK: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 160 UK: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 161 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 162 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 163 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 164 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 165 GERMANY: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 166 GERMANY: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 167 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 168 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 169 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 170 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 171 FRANCE: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 172 FRANCE: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 173 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 174 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 175 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 176 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 177 ITALY: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 178 ITALY: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 179 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 180 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 181 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 182 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 183 SPAIN: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 184 SPAIN: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 185 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 186 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 187 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 188 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 189 REST OF EUROPE: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 190 REST OF EUROPE: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 191 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 192 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 193 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 194 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 195 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 196 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 197 ASIA PACIFIC: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 199 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 200 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 201 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 202 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 203 CHINA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 204 CHINA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 205 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 206 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 207 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 208 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 209 JAPAN: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 210 JAPAN: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 211 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 212 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 213 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 214 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 215 INDIA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 216 INDIA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 217 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 218 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 219 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 220 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 221 AUSTRALIA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 222 AUSTRALIA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 223 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 224 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 225 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 226 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 227 REST OF ASIA PACIFIC: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 228 REST OF ASIA PACIFIC: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 229 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 230 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 231 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 232 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 233 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 234 LATIN AMERICA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 235 LATIN AMERICA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 236 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 237 MIDDLE EAST & AFRICA: MACROINDICATORS
  • TABLE 238 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 239 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2031 (USD MILLION)
  • TABLE 240 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2031 (USD MILLION)
  • TABLE 241 MIDDLE EAST & AFRICA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 242 MIDDLE EAST & AFRICA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 243 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 244 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET, JANUARY 2021-MAY 2025
  • TABLE 245 AUTOIMMUNITY DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 246 AUTOIMMUNITY DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 247 AUTOIMMUNITY DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
  • TABLE 248 AUTOIMMUNITY DIAGNOSTICS MARKET: TEST TYPE FOOTPRINT
  • TABLE 249 AUTOIMMUNITY DIAGNOSTICS MARKET: DISEASE TYPE FOOTPRINT
  • TABLE 250 AUTOIMMUNITY DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 251 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY PRODUCT AND DISEASE TYPE
  • TABLE 252 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY REGION
  • TABLE 253 AUTOIMMUNITY DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 254 AUTOIMMUNITY DIAGNOSTICS MARKET: DEALS, JANUARY 2021-MAY 2025
  • TABLE 255 AUTOIMMUNITY DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021-MAY 2025
  • TABLE 256 AUTOIMMUNITY DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2025
  • TABLE 257 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 258 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 259 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 260 ABBOTT LABORATORIES: PRODUCTS OFFERED
  • TABLE 261 REVVITY, INC.: COMPANY OVERVIEW
  • TABLE 262 REVVITY, INC.: PRODUCTS OFFERED
  • TABLE 263 REVVITY, INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2025
  • TABLE 264 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 265 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 266 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2025
  • TABLE 267 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-MAY 2025
  • TABLE 268 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2025
  • TABLE 269 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 270 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 271 SIEMENS HEALTHINEERS AG: PRODUCT APPROVALS, JANUARY 2021- MAY 2025
  • TABLE 272 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021- MAY 2025
  • TABLE 273 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 274 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 275 GRIFOLS S.A.: COMPANY OVERVIEW
  • TABLE 276 GRIFOLS S.A.: PRODUCTS OFFERED
  • TABLE 277 GRIFOLS S.A.: DEALS, JANUARY 2021- MAY 2025
  • TABLE 278 WERFEN S.A.: COMPANY OVERVIEW
  • TABLE 279 WERFEN S.A.: PRODUCTS OFFERED
  • TABLE 280 WERFEN S.A.: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 281 EXAGEN INC.: COMPANY OVERVIEW
  • TABLE 282 EXAGEN INC.: PRODUCTS OFFERED
  • TABLE 283 EXAGEN INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2025
  • TABLE 284 EXAGEN INC.: DEALS, JANUARY 2021-MAY 2025
  • TABLE 285 TRINITY BIOTECH PLC: COMPANY OVERVIEW
  • TABLE 286 TRINITY BIOTECH PLC: PRODUCTS OFFERED
  • TABLE 287 TECAN GROUP LTD.: COMPANY OVERVIEW
  • TABLE 288 TECAN GROUP LTD.: PRODUCTS OFFERED
  • TABLE 289 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 290 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 291 DANAHER CORPORATION: DEALS, JANUARY 2021- MAY 2025
  • TABLE 292 BIOSYNEX SA: COMPANY OVERVIEW
  • TABLE 293 BIOSYNEX SA: PRODUCTS OFFERED
  • TABLE 294 BIOSYNEX SA: DEALS, JANUARY 2021- MAY 2025
  • TABLE 295 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 296 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 297 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021- MAY 2025
  • TABLE 298 BIOMERIEUX SA: COMPANY OVERVIEW
  • TABLE 299 BIOMERIEUX SA: PRODUCTS OFFERED
  • TABLE 300 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 301 DIASORIN S.P.A.: PRODUCTS OFFERED
  • TABLE 302 DIASORIN S.P.A.: DEALS, JANUARY 2021- MAY 2025
  • TABLE 303 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 304 SD BIOSENSOR, INC.: COMPANY OVERVIEW
  • TABLE 305 CAMBRIDGE LIFE SCIENCES LTD.: COMPANY OVERVIEW
  • TABLE 306 A. MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW
  • TABLE 307 SEBIA: COMPANY OVERVIEW
  • TABLE 308 KRONUS: COMPANY OVERVIEW
  • TABLE 309 ERBA GROUP: COMPANY OVERVIEW
  • TABLE 310 AESKU.GROUP GMBH: COMPANY OVERVIEW
  • TABLE 311 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.: COMPANY OVERVIEW
  • TABLE 312 EPITOPE DIAGNOSTICS INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 AUTOIMMUNITY DIAGNOSTICS MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARIES
  • FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 7 AUTOIMMUNITY DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • FIGURE 9 AUTOIMMUNITY DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS
  • FIGURE 10 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2031 (USD MILLION)
  • FIGURE 11 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2031 (USD MILLION)
  • FIGURE 12 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2031 (USD MILLION)
  • FIGURE 13 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2031 (USD MILLION)
  • FIGURE 14 AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2031 (USD MILLION)
  • FIGURE 15 RISING PREVALENCE OF AUTOIMMUNE DISEASES AND INCREASING ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES TO PROPEL MARKET
  • FIGURE 16 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 17 AUTOANTIBODIES AND IMMUNOLOGIC TESTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 18 SYSTEMIC AUTOIMMUNE DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 19 CLINICAL LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 21 AUTOIMMUNITY DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 PATENT ANALYSIS FOR IMMUNOASSAYS (JANUARY 2014-DECEMBER 2024)
  • FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING ASSEMBLY PHASES
  • FIGURE 24 AUTOIMMUNITY DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 25 AUTOIMMUNITY DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 26 AUTOIMMUNITY DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR AUTOIMMUNITY DIAGNOSTICS PRODUCTS
  • FIGURE 28 KEY BUYING CRITERIA FOR AUTOIMMUNITY DIAGNOSTICS PRODUCTS
  • FIGURE 29 AUTOIMMUNITY DIAGNOSTICS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 30 NUMBER OF DEALS & FUNDING ACTIVITIES IN AUTOIMMUNITY DIAGNOSTICS MARKET
  • FIGURE 31 MARKET POTENTIAL OF AI IN AUTOIMMUNITY DIAGNOSTICS MARKET
  • FIGURE 32 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS SNAPSHOT
  • FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET (2022-2024)
  • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET (2024)
  • FIGURE 36 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 37 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 38 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 39 EV/EBITDA OF KEY VENDORS
  • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 41 AUTOIMMUNITY DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS
  • FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2024)
  • FIGURE 44 REVVITY, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 48 GRIFOLS S.A.: COMPANY SNAPSHOT (2024)
  • FIGURE 49 WERFEN S.A: COMPANY SNAPSHOT (2024)
  • FIGURE 50 EXAGEN INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 51 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 52 TECAN GROUP LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 54 BIOSYNEX SA: COMPANY SNAPSHOT (2024)
  • FIGURE 55 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 56 BIOMERIEUX SA: COMPANY SNAPSHOT (2024)
  • FIGURE 57 DIASORIN S.P.A.: COMPANY SNAPSHOT (2024)